PharmGKB summary: isoniazid pathway, pharmacokinetics

被引：42
作者：
Klein, Daniel J. [1 ,3 ]
Boukouvala, Sotiria [4 ]
McDonagh, Ellen M. [1 ]
Shuldiner, Scott R. [1 ]
Laurieri, Nicola [5 ]
Thorn, Caroline F. [1 ]
Altman, Russ B. [1 ,2 ]
Klein, Teri E. [1 ]
机构：
[1] Stanford Univ, Dept Genet, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[4] Democritus Univ Thrace, Dept Mol Biol & Genet, Alexandroupolis, Greece
[5] Univ Oxford, Dept Pharmacol, Oxford, England
来源：
PHARMACOGENETICS AND GENOMICS | 2016年 / 26卷 / 09期
关键词：
anti-tuberculosis drug-induced hepatotoxicity; cytochrome P450 2E1; GSTT1; GSTM1; isoniazid; N-acetyltransferase; 2; pharmacokinetics; DRUG-INDUCED HEPATOTOXICITY; INDUCED LIVER-INJURY; N-ACETYLTRANSFERASE; S-TRANSFERASE M1; CYTOCHROME-P450; 2E1; GENOTYPE; GSTT1 GENETIC POLYMORPHISMS; SUSCEPTIBILITY RISK-FACTOR; HEPATIC BILE-ACIDS; ANTITUBERCULOSIS DRUGS; TUBERCULOSIS PATIENTS;
D O I：
10.1097/FPC.0000000000000232
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
[No abstract available]
引用
收藏
页码：436 / 444
页数：9
相关论文
共 114 条
  • [1] NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients
    An, Hui-Ru
    Wu, Xue-Qiong
    Wang, Zhong-Yuan
    Zhang, Jun-Xian
    Liang, Yan
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (06): : 535 - 543
  • [2] [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
  • [3] [Anonymous], 2008, TUBERCULOSIS, V88, P85
  • [4] Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells
    Apostolova, N.
    Gomez-Sucerquia, L. J.
    Moran, A.
    Alvarez, A.
    Blas-Garcia, A.
    Esplugues, J. V.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (08) : 2069 - 2084
  • [5] NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
    Azuma, Junichi
    Ohno, Masako
    Kubota, Ryuji
    Yokota, Soichiro
    Nagai, Takayuki
    Tsuyuguchi, Kazunari
    Okuda, Yasuhisa
    Takashima, Tetsuya
    Kamimura, Sayaka
    Fujio, Yasushi
    Kawase, Ichiro
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (05) : 1091 - 1101
  • [6] Baselt R.C., 2002, Disposition of Toxic Drugs and Chemicals in Man, V6th
  • [7] Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid
    Becker, C.
    Dressman, J. B.
    Amidon, G. L.
    Junginger, H. E.
    Kopp, S.
    Midha, K. K.
    Shah, V. P.
    Stavchansky, S.
    Barends, D. M.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (03) : 522 - 531
  • [8] Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis
    Ben Mahmoud, L.
    Ghozzi, H.
    Kamoun, A.
    Hakim, A.
    Hachicha, H.
    Hammami, S.
    Sahnoun, Z.
    Zalila, N.
    Makni, H.
    Zeghal, K.
    [J]. PATHOLOGIE BIOLOGIE, 2012, 60 (05): : 324 - 330
  • [9] Inhibition of Mitochondrial Function by Efavirenz Increases Lipid Content in Hepatic Cells
    Blas-Garcia, Ana
    Apostolova, Nadezda
    Ballesteros, Daniel
    Monleon, Daniel
    Morales, Jose M.
    Rocha, Milagros
    Victor, Victor M.
    Esplugues, Juan V.
    [J]. HEPATOLOGY, 2010, 52 (01) : 115 - 125
  • [10] Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress
    Boelsterli, Urs A.
    Lee, Kang Kwang
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (04) : 678 - 687
12345678910